Diligence memo · auto-generated · as of July 3, 2026

Maryland Proton Treatment Holdings, LLC

Maryland Proton Treatment Holdings, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Maryland Proton Treatment Holdings, LLC operates in Hospitals and Physicians, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Maryland Proton Treatment Holdings, LLC has raised $35M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $33M on 2010-10-29.

Most recent recorded round closed around 2010-10-29.

Valuation (modeled)modeled

Provath models Maryland Proton Treatment Holdings, LLC at approximately $677M (range $81M–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.52× the median modeled value of Series B Hospitals and Physicians companies in 2010–2012 (9 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 15.7 yr ago; this sector typically re-raises about every 12 months.

Silent for over 3× the sector's normal cadence.

The last round was 3.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 92% of Hospitals and Physicians peers (599 compared).

Modeled value ranks above 96% of those peers.

Closest niche peers: Emerus Holdings, Inc., Georgia Proton Treatment Center, LLC, U.S. Renal Care Inc, Emergency Medicine Physicians, LLC, Forest Park Medical Center at Frisco, LLC.

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.